This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignee: Medimmune Limited. Active years: 2018-2021.
Company Filing History:
Years Active: 2018-2021
Title: The Innovations of Daniel E Berkowitz
Introduction
Daniel E Berkowitz is a notable inventor based in Baltimore, MD (US). He has made significant contributions to the field of cardiovascular medicine through his innovative research and patented inventions. With a total of 2 patents, Berkowitz has focused on developing antibodies that target specific proteins involved in cardiovascular disorders.
Latest Patents
Berkowitz's latest patents include groundbreaking work on antibodies specific for LOX1, which play a crucial role in the treatment of various cardiovascular disorders. This disclosure provides LOX1 binding proteins, such as anti-LOX1 antibodies, along with compositions and methods for their production. These LOX1-binding proteins are designed to inhibit or antagonize LOX1 activity. Furthermore, the patents detail methods for diagnosing and treating conditions associated with atherosclerosis, thrombosis, coronary artery disease (CAD), ischemia, myocardial infarction, acute coronary syndrome (ACS), stroke, reperfusion injury, restenosis, peripheral vascular disease, hypertension, heart failure, chronic inflammation, angiogenesis, preeclampsia, cancer, and other LOX1-mediated diseases and conditions.
Career Highlights
Berkowitz is currently associated with MedImmune Limited, where he continues to advance his research in the field of immunology and cardiovascular health. His work has been instrumental in developing therapeutic strategies that address critical health issues.
Collaborations
Throughout his career, Berkowitz has collaborated with esteemed colleagues, including Andrew Grier Buchanan and Peter Cariuk. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.
Conclusion
Daniel E Berkowitz's contributions to the field of cardiovascular medicine through his patented inventions highlight his dedication to improving health outcomes. His innovative work with LOX1-binding proteins represents a significant advancement in the treatment of cardiovascular disorders.